Company Overview and News

 
Should iShares Morningstar Small-Cap ETF (JKJ) Be on Your Investing Radar?

2018-05-08 zacks
Looking for broad exposure to the Small Cap Blend segment of the US equity market? You should consider the iShares Morningstar Small-Cap ETF (JKJ - Free Report) , a passively managed exchange traded fund launched on 06/28/2004.

 
iShares S&P Small-Cap 600 Value ETF: It Works, But Do You Need It?

2018-04-06 seekingalpha
Discussion of the iShares S&P Small-Cap 600 Value ETF, a diversified ETF focused on small cap stocks which are thought to be undervalued.

 
5 Ways To Beat The Market: Part 1

2018-01-04 seekingalpha
In an ongoing series of articles, I have highlighted five buy-and-hold strategies that have historically outperformed the S&P 500.

 
Small-Cap ETFs Face Off: IWM Versus IJR

2017-12-12 zacks
Small-cap stocks, which were lagging in the first half of the year, staged a nice comeback over the past three months on talks of tax reform. The optimism intensified after the House and Senate passed the tax bill, though the version of the both the bills differ on some fronts. With the House and Senate in negotiation on the consolidated bill, Republicans are now closer to finalize the $1.5-trillion tax reform by the end of the year.

 
Asset Report of September: Small Caps Rule

2017-10-04 zacks
The month of September saw investors being equally enthusiastic about stocks and bonds. While upbeat global economic readings boosted equities, North Korea’s nuke-related tensions boosted investors’ interests in treasuries too. Chances of the extension of the OPEC output cut deal and improvement in the demand scenario also kept the energy space steady. Against this backdrop, let’s find out the top gainers and losers in terms of asset growth in September (source: etf.

 
Introducing The ETF Focus Ultra Low Cost Core Portfolio

2017-09-14 seekingalpha
Many investors want to simply set themselves up with a solid portfolio foundation with a long-term focus that requires little hassle or maintenance.

1
7 ETFs To Complete My Monthly Core Dividend Portfolio

2017-08-07 seekingalpha
In a recent article, I laid out 20 top stocks with which to build a dividend-focused portfolio, and also included 2 "bonus" stocks to consider.

 
S&P & Russell Say No to Snap: Impact on ETFs

2017-08-02 zacks
Snapchat Inc. (SNAP - Free Report) has been hitting headlines in recent weeks with a wave of bad news as its shares hit an all-time low of $13.07, tumbling more than 25% over the past one month. In fact, the stock is currently trading 23% below its IPO price. The latest setback came when the social media network was dumped from the S&P 500 Index due to changes in the S&P Dow Jones Indices methodology.

 
3 Top Index Funds in July

2017-07-11 fool
Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services.

 
The July Trade In Small Caps

2017-06-24 seekingalpha
However, the index you choose matters. The article discusses structural differences between the two leading small-cap indices tracked by small-cap funds.

 
Should Dividend Growth Investors Own ETFs?

2017-05-20 seekingalpha
If you haven't yet read Mike Nadel's latest two-part compilation effort regarding "core" positions (I, II), you should really take the time to do so. It's an interesting series that polls a large group of SA's dividend crowd, revealing diverse thoughts on the subject, including the panel's current holdings deemed as core.

 
Tracking The Smart Beta Horse Race With ETFs

2017-03-24 seekingalpha
How's that factor strategy been working for 'ya lately? That's a topical question for a growing number of investors as "smart beta" products play a bigger role in portfolio design. You may not be drinking the factor Kool-Aid, but it's still worthwhile to check in on these risk premia periodically for some context on what's driving equity performance generally. With that in mind, let's review a set of eight ETFs that represent the usual suspects in the US equity factor space.

 
iShares Russell 2000 ETF: Lacking Quality

2017-01-18 seekingalpha
The iShares Russell 2000 ETF (NYSEARCA:IWM) returned 8.5% during the past 15 years, a great result compared to the 6.8% return of the S&P 500. However, the iShares Core S&P Small-Cap ETF (NYSEARCA:IJR) returned 10.1%. How can two index ETFs that track similar groups of stocks have such a large discrepancy in performance? The answer comes down to quality.

 
5 Ways To Beat The Market In 2017 And Beyond: Part I

2017-01-03 seekingalpha
In an ongoing series of articles, I have highlighted five buy-and-hold strategies that have historically outperformed the S&P 500.

 
Inside JPMorgan's U.S. Small Cap ETF

2016-12-07 zacks
The U.S. stock market staged a rally led by small-cap stocks after Donald Trump won the presidential election. The Russell 2000 index tracking small-cap stocks recorded its longest rally in two decades. Among the many things, the President-elect has promised to introduce a burst of stimulus by increasing infrastructure spending package, easing regulations and tax cuts with an aim of accelerating economic growth and creating more jobs in the country (read: ETFs & Stocks That Topped or Flopped After Trump Won).

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

13h - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

13h - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...